Atomo Diagnostics Limited (ASX:AT1)
Australia · Delayed Price · Currency is AUD 0.0210
+0.0010 (5.00%)
Sep 18, 2025, 4:10 PM AEST
Atomo Diagnostics Company Description
Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide.
The company offers RDT platforms, including AtomoRapid Pascal, Curie, Galileo, and Elion for blood tests.
It also offers Atomo application, a custom mobile application for self-test users, as well as provides digital health solutions.
In addition, it provides HIV Rapid self-Tests. Atomo Diagnostics Limited was incorporated in 2010 and is headquartered in Leichhardt, Australia.
Atomo Diagnostics Limited
| Country | Australia |
| Founded | 2010 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 85 |
| CEO | John Kelly |
Contact Details
Address: 3-5 George Street Leichhardt, 2040 Australia | |
| Phone | 61 2 9099 4750 |
| Website | atomodiagnostics.com |
Stock Details
| Ticker Symbol | AT1 |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000080327 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| John Michael Kelly | Founder, Chief Executive Officer, MD and Interim Chair |
| Chandra Sukumar | Chief Operating Officer |
| Suzy Elhlou | Finance Manager |
| Mathew Watkins C.A. | Company Secretary |